Immersive Virtual Reality & Obsessive Compulsive Disorder

Status Active, not recruiting

Clinical Trial Summary

Immersive VR (IVR) is based on the generation and projection of images from different perspectives. Obsessive Compulsive Disorder (OCD) is considered one of the 5 most common mental disorders and one of the 20 most disabling diseases according to the World Health Organization (WHO). Its vital prevalence is about 2.5%. This study aims to establish the effectiveness of a cognitive-behavioral intervention - individual and group - using IVR in patients diagnosed with OCD compared to a group receiving standard treatment by the Mental Health Center. A sample will be obtained from the list of all patients registered in the Mental Health Service of the University Hospital of Vic (Vic, Catalonia) with the primary or secondary diagnosis of Obsessive Compulsive Disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM 5) and in active treatment status in the period between January 2021 and January 2023. Randomized controlled clinical trial. Variables: sociodemographic, clinical, OCD symptom follow-up and quality of life. Measurement instruments: Yale-Brown Obsessive Compulsive Scale (Y-BOCS), State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), Immersive Tendencies Questionnaire (ITQ), Presence Questionnaire, EuroQoL-5D (EQ-5D). Inclusion criteria: Patients over 18 years of age with a primary or secondary diagnosis of Obsessive Compulsive Disorder with one of the following specifiers: with good or acceptable introspection (1) or with little introspection (2); persons with current activity at the Mental Health Center. Exclusion criteria: patients with a diagnosis of intellectual disability, autistic spectrum disorder, active substance-related disorders, neuro-cognitive disorder and/or severe personality disorder; acute psychopathological decompensation; insufficient command of Catalan and/or Spanish; advanced disease and/or disease that significantly hinders the follow-up of the intervention.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05841017
Study type	Interventional
Source	Consorci Hospitalari de Vic
Contact
Status	Active, not recruiting
Phase	N/A
Start date	February 13, 2023
Completion date	February 12, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04934007` - Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder	N/A
Recruiting	`NCT04071990` - Family Involvement in CBGT of OCD: a Randomized Controlled Trial	N/A
Completed	`NCT02541968` - Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder	N/A
Recruiting	`NCT05651295` - A Precision Medicine Approach to Target Engagement for Emotion Regulation	N/A
Recruiting	`NCT05391503` - Light Therapy for Obsessive-compulsive Disorder (OCD)	N/A
Recruiting	`NCT04539951` - Pragmatic Trial of Obsessive-compulsive Disorder	Phase 2
Completed	`NCT03416504` - Methods for Managing Intrusive Thoughts	N/A
Not yet recruiting	`NCT06029738` - Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD	N/A
Recruiting	`NCT02844049` - European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS	N/A
Terminated	`NCT02909660` - What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder	N/A
Completed	`NCT02911324` - Cannabinoid Medication for Adults With OCD	Phase 1/Phase 2
Completed	`NCT02217995` - Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients	N/A
Terminated	`NCT02234011` - A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder	Phase 2
Withdrawn	`NCT01953042` - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders	N/A
Completed	`NCT02655926` - Deep Brain Stimulation for Severe Obsessive Compulsive Disorder	N/A
Completed	`NCT00742664` - Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project	Phase 1/Phase 2
Terminated	`NCT00758966` - Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder	Phase 2
Completed	`NCT04919785` - Deep Brain Stimulation in Severe Obsessive-compulsive Disorder	N/A
Completed	`NCT00523718` - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder	Phase 2
Completed	`NCT00074815` - Treatment of Obsessive Compulsive Disorder in Children	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.